These findings demonstrate that micromolar concentrations of cysteamine treatment specifically inhibit MMP activity and TGM2 expression, subsequently decreasing MMP2, MMP9, and MMP14 protein levels in GBM cells. This evidence concerns the gene MMP9 and glioblastoma.